Serious adverse events
| Intravenous rtPA (IVT) | IVT+MT | |
|---|---|---|
| n | 32 | 33 |
| No. with any SAE | 11 (34%) | 15 (45%) |
| No. of SAEs reported | 15 | 21 |
| Probably or definitely related to study procedures | 3 | 2 |
| Fatal SAEs | 4 | 7 |
| No. fatal SAEs <7 days after onset | 1 | 6 |
| Fatal neurological events <7 days after onset | 1 | 4 |
| Intracerebral haemorrhage events | ||
| Any ICH | 3 | 3 |
| SICH | 0 | 0 |
| ICH events on CT | ||
| HI1 or HI2 | 12 | 13 |
| PH1 | 1 | 1 |
| PH2 | 0 | 2 |
| Non-ICH SAEs | 12 | 18 |
| Anaemia | 0 | 1 |
| MI/acute coronary syndrome | 2 | 1 |
| Gingival bleeding | 1 | 0 |
| Pneumonia | 4 | 5 |
| Brain swelling | 2 | 4 |
| Recurrent ischaemic stroke | 0 | 3 |
| Neurological deterioration, not definitely ICH or swelling | 0 | 1 |
| Other | 3 (CCF, UTI, psychiatric) | 3 (pulmonary embolism, osteoarthritis, UTI) |
CCF, congestive cardiac failure; HI1/HI2, haemorrhagic infarction types 1 or 2; ICH, intracerebral haemorrhage; IV, intravenous; MI, myocardial infarction; MT, mechanical thrombectomy; PH1/2, parenchymal haematoma types 1 or 2; rtPA, recombinant tissue plasminogen activator; SAE, serious adverse event; SICH, symptomatic intracerebral haemorrhage; UTI, urinary tract infection.